C 2207
Alternative Names: C-2207Latest Information Update: 08 May 2024
At a glance
- Originator JW Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 13 Jan 2024 JW Pharmaceutical completes a phase-I clinical trial in Unspecified (In volunteers, Combination therapy) in South Korea (PO) (NCT06378684)
- 13 Jan 2024 JW Pharmaceutical completes a phase-I clinical trial in Unspecified (In volunteers, Monotherapy) in South Korea (PO) (NCT06378684)